Anti-KLKB1 therapeutic antibody (Pre-made Lanadelumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Lanadelumab (INN; trade name Takhzyro) is a human monoclonal antibody (class IgG1 kappa)that targets plasma kallikrein (pKal) in order to promote prevention of angioedema in patients with hereditary angioedema. Lanadelumab, was approved in the United States as the first monoclonal antibody indicated for prophylactic treatment to prevent hereditary angioedema (HAE) attacks. Takhzyro is the first treatment for hereditary angioedema (HEA) prevention made by using cells within a lab, not human plasma.[8] The US Food and Drug Administration approved the use of lanadelumab on 23 August 2018 for patients that are 12 years and older and suffering from either type I or type II hereditary angioedema (HEA). Administration of the medication is done through 1 subcutaneous injection at a dose of 300 milligrams every 2 weeks (every 4-week dosing can be considered in specific patients).

Order informatioin

Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-294-1mg	1mg	3090
GMP-Bios-ab-294-10mg	10mg	21890
GMP-Bios-ab-294-100mg	100mg	148000
GMP-Bios-ab-294-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Anti-KLKB1 therapeutic antibody (Pre-made Lanadelumab biosimilar,Whole mAb)
INN Name	Lanadelumab
Target	KLKB1
Format	Whole mAb
Derivation	Human
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Approved
Est. Status	NFD
100% SI Structure	4pub:HL/4ogy:HL:MN/4ogx:HL
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2015
Year Recommended	2016
Companies	Dyax;Shire;Takeda
Conditions Approved	Hereditary angioedema
Conditions Active	na
Conditions Discontinued	Diabetic macular oedema
Development Tech	na